BB Biotech AG

BION

CH0038389992

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 11:30:46 2024-12-02 am EST			5-day change	1st Jan Change
37.55 ^CHF	+0.54%		+3.59%	-12.16%

Oct. 25	BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
Oct. 25	BB Biotech's Q3 Loss Widens; Operating Income Drops	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about BB Biotech AG

BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Oct. 25	CI
BB Biotech's Q3 Loss Widens; Operating Income Drops	Oct. 25	MT
BB Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Jul. 26	CI
BB Biotech Returns to H1 Profit; Operating Income Up	Jul. 26	MT
Jazz Pharmaceuticals plc Elect Laura Hamill to the Board of Directors	Jul. 25	CI
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	Apr. 27	CI
Switzerland's BB Biotech Swings to Q1 Profit; Operating Income Jumps	Apr. 26	MT
BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	Feb. 14	CI
BB Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
BB Biotech Names Successor to Outgoing Chair	Jan. 19	MT
BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-20	CI
Switzerland's BB Biotech Swings to Q3 Loss; Operating Income Shrinks	23-10-20	MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	23-10-20	CI
BB Biotech Shares to be Suspended from Euronext Star Milan Pending Delisting	23-08-21	MT
BB Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-21	CI
Switzerland's BB Biotech to Scrap Listing on Italian Bourse	23-07-21	MT
BB Biotech Logs Decline in H1 Loss, Operating Income	23-07-21	MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	23-07-21	CI
BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-21	CI
Europeans contrasted; gold below USD2,000 threshold	23-04-21	AN
Europeans without momentum ahead of PMIs	23-04-21	AN
BB Biotech Posts Lower Q1 Loss; Operating Income Falls	23-04-21	MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	23-04-21	CI
Europeans down; auto sector suffers	23-04-20	AN

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companyâs portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-02-21 - Q4 2024 Earnings Release

More about the company